The companies that will be represented are Acciona, BME, CIE Automotive, Ebro Foods, Hispania, Inmobiliaria Colonial, LAR España, Mediaset, Merlin Properties, Metrovacesa, Parques Reunidos, PharmaMar and Sacyr, which have a combined market value of €35 Billion.
Seventh edition of the “Spanish Small & Midcaps Conference”.
Tuesday, 12 June, marks the start of the seventh edition of the “Spanish Small & Midcaps Conference”, co-hosted by BME and JB Capital Markets in New York. The Conference will bring together the senior managers of 13 Spanish listed companies of medium and small capitalisation with over 40 US institutional investors interested in exploring opportunities in the Spanish market.
Through the more than 100 one-on-one meetings scheduled, top international investors will have the opportunity to meet Spanish companies in order to provide them with information for their investment decisions.
...
PharmaMar Recibe el Ok de la FDA Para Iniciar Fase I con PM54 en Combi con Inmuno Para Posible Tratamiento . PARA EI RELEVO DE LURBINECTEDIN ESTABAN PM184 Y PM14 AMBOS RETIRADOS POR LA CIA. AHORA HAY OTROS DOS FÁRMACOS EN FASE I EN EL INTENTO DE RELEVAR A LURBINECTEDIN : PM54 Y PM534 ... EL PROBLEMA ES QUE AMBOS AÚN ESTAN EN FASE I CON TODO LO QUE ESTO IMPLICA EN CUESTIÓN DE PLAZOS ... YA QUE PARA REALUZAR 3 FASES CLÍNICAS HACEN FALTA DE 12 A 15 AÑOS ... NOS IRÍAMOS AL 2040.
12 junio 2018
Zepsyre ( Lurbinectedin ) Focus - Small Cell Lung Cancer Virtual Roundtable .
In this clip the panel goes over newly released data concerning Lurbinectedin.
Description : H. Jack West, MD, Medical Director, Thoracic Oncology Program, Swedish Institute, Founder & President, Grace Global Resource for Advancing Cancer Education leads this section on immunotherapy of a three part series dedicated to the advancements in treatment of small cell lung cancer.
The discussants include Anne Chiang MD, PhD, Associate Professor, Yale University School of Medicine, Deputy Chief Medical Officer, Chief Network Officer, Smilow Cancer Hospital, Taofeek Owonikoko, MD, PhD, MSCR, Professor, Department of Hematology & Medical Oncology, Emory University School of Medicine, Co-Chair, Clinical & Translational Review Committee, Winship Cancer Institute of Emory University, Jeff Petty, MD, Director, Thoracic Oncology Program, Professor of Medicine, Section on Hematology and Oncology, Wake Forest School of Medicine.
In this clip the panel goes over newly released information concerning immunotherapy for small cell lung cancer patients.
Description : H. Jack West, MD, Medical Director, Thoracic Oncology Program, Swedish Institute, Founder & President, Grace Global Resource for Advancing Cancer Education leads this section on immunotherapy of a three part series dedicated to the advancements in treatment of small cell lung cancer.
The discussants include Anne Chiang MD, PhD, Associate Professor, Yale University School of Medicine, Deputy Chief Medical Officer, Chief Network Officer, Smilow Cancer Hospital, Taofeek Owonikoko, MD, PhD, MSCR, Professor, Department of Hematology & Medical Oncology, Emory University School of Medicine, Co-Chair, Clinical & Translational Review Committee, Winship Cancer Institute of Emory University, Jeff Petty, MD, Director, Thoracic Oncology Program, Professor of Medicine, Section on Hematology and Oncology, Wake Forest School of Medicine.
In this clip the panel goes over newly released information concerning immunotherapy for small cell lung cancer patients.
Suscribirse a:
Comentarios (Atom)



